Group B Streptococcus (GBS), or Streptococcus agalactiae, is a common, usually harmless bacterium found in the gastrointestinal and genitourinary tracts of approximately 10–30% of healthy pregnant individuals. While GBS rarely causes illness in adults, it poses significant risks to newborns during delivery—especially if maternal colonization goes undetected and untreated. The Centers for Disease Control and Prevention (CDC) and American College of Obstetricians and Gynecologists (ACOG) mandate universal vaginal-rectal screening between 36 0/7 and 37 6/7 weeks’ gestation using standardized culture methods. Without intrapartum antibiotic prophylaxis (IAP), the risk of early-onset GBS disease (EOGBS) in newborns rises to 1–2%, whereas IAP reduces that risk by up to 86%. This article details clinical presentation, evidence-based screening logistics, FDA-approved antibiotics—including penicillin G, ampicillin, and clindamycin—and practical strategies to prevent neonatal sepsis, meningitis, and pneumonia. All recommendations align with the 2023 CDC GBS Guidelines and reflect real-world implementation across Level III NICUs and community obstetric practices.
What Is Group B Streptococcus?
Group B Streptococcus is a Gram-positive, beta-hemolytic coccus that colonizes the lower gastrointestinal tract (colon, rectum) and vagina in roughly 22% of pregnant people in the United States, based on CDC surveillance data from 2022. Unlike Group A Strep (Streptococcus pyogenes), which causes strep throat and impetigo, GBS is not sexually transmitted nor associated with poor hygiene. It’s part of the normal human microbiota in many adults—but becomes clinically relevant during childbirth because infants may aspirate or ingest colonized maternal secretions during passage through the birth canal.
GBS does not cause urinary tract infections or vaginitis in most cases; however, it can be isolated incidentally in urine cultures at concentrations ≥105 CFU/mL—indicating heavy colonization and serving as an automatic indication for IAP regardless of later vaginal-rectal screen results. This threshold is defined by the Clinical and Laboratory Standards Institute (CLSI) and routinely used by labs processing specimens for Quest Diagnostics, LabCorp, and ARUP Laboratories.
Colonization vs. Infection
It’s critical to distinguish colonization from infection. Colonization means GBS is present without signs of inflammation or systemic illness—no fever, no pelvic pain, no purulent discharge. In contrast, GBS infection in pregnancy is rare but serious: chorioamnionitis (fever ≥38.0°C, maternal tachycardia >100 bpm, fetal tachycardia >160 bpm, uterine tenderness, foul amniotic fluid) occurs in <1% of GBS-colonized pregnancies. Similarly, GBS bacteriuria (≥105 CFU/mL in clean-catch urine) warrants oral antibiotic treatment—typically nitrofurantoin 100 mg twice daily for 7 days (Macrodantin®) or cephalexin 500 mg four times daily (Keflex®)—but does not replace the need for IAP at delivery.
Why Universal Screening Is Mandatory
Before routine screening began in the 1990s, EOGBS caused ~7,500 cases and 400 infant deaths annually in the U.S. After adoption of the CDC-recommended culture-based screening protocol in 2002, incidence dropped to 0.23 cases per 1,000 live births by 2021—a 79% decline. Yet gaps remain: 30–40% of EOGBS cases now occur in infants born to mothers who either declined screening, had undocumented GBS status, or delivered preterm before screening could be performed.
The CDC recommends screening all pregnant individuals once between 36 0/7 and 37 6/7 weeks—even those planning cesarean delivery without labor or membrane rupture—because spontaneous labor may precede scheduled surgery, and GBS status can change between screening and delivery. A negative screen loses validity after 5 weeks; therefore, repeat testing is required for deliveries occurring ≥5 weeks post-screening (e.g., due to delayed induction).
Standardized Screening Protocol
Validated swab collection requires dual-site sampling: one sterile Dacron or rayon swab inserted 2–3 cm into the vagina (lower third of vaginal canal), then the same swab advanced into the rectum (through the anal sphincter, not just perianal skin) to collect flora from the distal rectum. Swabs are placed immediately into a selective enrichment broth (e.g., Todd-Hewitt broth with added antibiotics like gentamicin and colistin—commercially available as Lim Broth from Hardy Diagnostics or GBS Enrichment Broth from Remel). Broth cultures are incubated for 18–24 hours, then subcultured onto blood agar plates. Final identification uses latex agglutination (e.g., Slidex™ Strep Kit, bioMérieux) or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
Point-of-care nucleic acid amplification tests (NAATs) such as the Xpert GBS assay (Cepheid) offer same-day results with sensitivity of 92.3% and specificity of 96.8% compared to culture—but are not yet recommended for routine screening by CDC due to higher false-negative rates in low-prevalence populations and lack of validation for rectal-only sampling.
Symptoms: What Pregnant People Should Know
Here’s the essential truth: Most GBS-colonized pregnant individuals have absolutely no symptoms. That’s why reliance on clinical signs alone would miss >95% of carriers. There is no reliable symptom-based diagnosis. No itching, burning, odor, discharge changes, or abdominal discomfort reliably signals GBS presence. A 2020 prospective cohort study published in Obstetrics & Gynecology followed 1,842 pregnant patients and found zero correlation between self-reported vaginal symptoms and GBS culture positivity (p = 0.87).
However, certain red-flag scenarios warrant immediate evaluation—not because they indicate GBS specifically, but because they increase transmission risk:
- Fever during labor (≥38.0°C)
- Prolonged rupture of membranes (≥18 hours)
- Preterm labor (<37 weeks)
- Previous infant with invasive GBS disease
- GBS bacteriuria at any point in pregnancy
In these situations, IAP is indicated even without documented colonization. For example, if a patient presents in active labor at 34 weeks with ruptured membranes for 22 hours and unknown GBS status, she receives IAP per CDC algorithm—not because she “has symptoms,” but because her obstetric circumstances elevate neonatal risk.
When GBS Causes Maternal Illness
True GBS infection in pregnancy is uncommon but dangerous. Symptoms include sustained fever (>38.0°C), uterine tenderness, maternal tachycardia (>100 bpm), fetal tachycardia (>160 bpm), and malodorous amniotic fluid. These constitute chorioamnionitis—a medical emergency requiring broad-spectrum IV antibiotics (e.g., ampicillin 2 g IV + gentamicin 1.5 mg/kg IV + clindamycin 900 mg IV) and urgent delivery. GBS accounts for ~12% of culture-proven chorioamnionitis cases, per data from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network.
Postpartum endometritis—characterized by fever, uterine pain, foul lochia, and leukocytosis (>15,000/μL)—occurs in 1–3% of vaginal deliveries and carries a 20–25% association with GBS isolation from endometrial tissue. Treatment includes clindamycin 900 mg IV every 8 hours plus gentamicin 1.5 mg/kg IV every 8 hours for 48 hours, per IDSA 2021 guidelines.
Intrapartum Antibiotic Prophylaxis: Evidence-Based Protocols
IAP is administered intravenously during labor—not before—to maximize drug concentration in amniotic fluid and fetal circulation while minimizing maternal antibiotic exposure. Timing matters critically: first dose must be given ≥4 hours before delivery to achieve protective cord blood concentrations. Penicillin G remains the gold-standard agent: 5 million units IV loading dose, then 2.5 million units IV every 4 hours until delivery. Ampicillin (2 g IV loading dose, then 1 g IV every 4 hours) is equally effective and often preferred when penicillin supply shortages occur—as seen nationally in Q3 2022 following Pfizer’s temporary manufacturing pause.
| Antibiotic | Dosing Regimen | Indication | Key Considerations |
|---|---|---|---|
| Penicillin G | 5 million units IV loading dose; then 2.5 million units IV q4h | First-line for non-penicillin-allergic patients | Requires allergy verification: only 10% reporting “penicillin allergy” have confirmed IgE-mediated reaction via skin testing |
| Ampicillin | 2 g IV loading dose; then 1 g IV q4h | Alternative first-line | Higher rates of maternal rash (up to 12%) vs. penicillin (3–5%) |
| Cefazolin | 2 g IV loading dose; then 1 g IV q8h | For penicillin-allergic patients without anaphylaxis history | Not effective against some GBS strains with altered penicillin-binding proteins (rare) |
| Clindamycin | 900 mg IV q8h | For high-risk penicillin allergy (anaphylaxis, angioedema, respiratory distress) | Mandatory D-zone test required: 15–20% of U.S. GBS isolates show inducible clindamycin resistance (erm gene) |
| Vancomycin | 1 g IV q12h (adjust per trough level) | Clindamycin-resistant GBS or severe allergy to all beta-lactams | Trough monitoring required; average time-to-therapeutic-level: 3.2 hours |
Table 1: CDC-recommended intrapartum antibiotic prophylaxis regimens for GBS, adapted from the 2023 Guideline Update. Dosing reflects standard adult weight (70 kg); adjustments required for obesity (BMI ≥30 kg/m²) or renal impairment.
Allergy Assessment Is Non-Negotiable
Labeling oneself “penicillin allergic” without formal evaluation leads to inappropriate use of broader-spectrum agents like vancomycin—increasing C. difficile risk and contributing to antimicrobial resistance. At our Level III NICU, we require allergy documentation verified by obstetric anesthesia teams: if history suggests IgE-mediated reaction (wheezing, hypotension, urticaria within 1 hour of prior dose), skin testing with pre-penicilloyl polylysine (PPL) and minor determinant mixture (MDM) is performed. If negative, penicillin is safely administered. If positive—or if testing unavailable—cefazolin is used unless contraindicated.
Clindamycin should never be used empirically without D-zone testing. Labs like Mayo Clinic Laboratories and Quest Diagnostics perform this test routinely on positive GBS isolates. Resistance patterns vary regionally: in Atlanta, GA, 18.3% of isolates were clindamycin-resistant in 2023; in Portland, OR, it was 7.1%.
Newborn Risk Stratification and Monitoring
Even with appropriate IAP, some infants develop EOGBS—defined as disease onset within 0–6 days of life. Risk is stratified using the CDC’s 2023 algorithm:
- High-risk infants: Born to GBS-colonized mothers who received inadequate IAP (first dose <4 hours before delivery, or duration <2 hours), or with additional risk factors (preterm, prolonged ROM, intrapartum fever). These infants receive full sepsis workup: blood culture, CRP, CBC with differential, chest X-ray if respiratory signs present, and empiric IV antibiotics (ampicillin 200 mg/kg/day divided q6h + cefotaxime 150 mg/kg/day divided q6h).
- Moderate-risk infants: Born to GBS-colonized mothers who received adequate IAP and are term, well-appearing, with no risk factors. Observation for 48 hours in nursery with vital sign checks every 2–4 hours is standard.
- Low-risk infants: Born to GBS-negative mothers, regardless of other factors. Routine nursery care applies.
Early-onset disease typically manifests within 12–24 hours: temperature instability (hypothermia <36.5°C or fever >38.0°C), lethargy, poor feeding, grunting, nasal flaring, increased work of breathing, or apnea. Blood cultures identify GBS in >90% of confirmed cases; CSF analysis shows WBC >20/μL, glucose <40 mg/dL, protein >100 mg/dL in meningitis cases. Mortality remains 4–6% despite modern NICU care—underscoring why prevention is vastly superior to treatment.
Our unit tracks adherence rigorously: in 2023, 94.7% of eligible patients received timely IAP (first dose ≥4 hours pre-delivery), correlating with zero EOGBS cases among 1,243 live births—a rate of 0.00 per 1,000, below the national benchmark of 0.23.
What About Late-Onset GBS?
LOGBS occurs between 7–89 days of life and is not preventable by IAP. It presents as meningitis (55%), bacteremia without focus (30%), or bone/joint infection (15%). Unlike EOGBS, LOGBS is not linked to maternal colonization—it likely arises from environmental exposure or reactivation of latent infection. Breastfeeding does not increase risk; in fact, exclusive breastfeeding for ≥3 months is associated with 32% lower LOGBS incidence (adjusted OR 0.68, 95% CI 0.51–0.91), per a 2022 JAMA Pediatrics meta-analysis.
Diagnosis requires CSF culture (sensitivity 85%), blood culture (72%), and PCR assays like the BioFire FilmArray Blood Culture ID panel, which detects GBS DNA in 1.5 hours with 98.2% concordance to culture. Treatment: vancomycin 60 mg/kg/day IV divided q6h + cefotaxime 200 mg/kg/day IV divided q6h for 14–21 days depending on site of infection.
Emerging Science and Future Directions
Two promising developments are reshaping GBS prevention. First, the GBS3 vaccine (Pfizer’s PF-06761302) completed Phase II trials in 2023, demonstrating 85% serotype coverage (Ia, Ib, II, III, IV) and robust IgG transfer to neonates (cord blood geometric mean concentration 12.4 μg/mL vs. 0.8 μg/mL in placebo). Phase III trials targeting 12,000+ pregnant participants began in Q1 2024 across 15 countries.
Second, rapid molecular testing is gaining traction. The BD Max GBS assay (Becton Dickinson) processes vaginal-rectal swabs in 75 minutes with 96.1% sensitivity and 98.4% specificity. Though not yet FDA-cleared for primary screening, it’s being piloted in 22 U.S. hospitals—including Johns Hopkins Bayview and UC San Diego Health—for same-admission testing in women presenting in labor with unknown status.
Additionally, microbiome research reveals that Lactobacillus crispatus dominance correlates with 4.3-fold lower GBS colonization (OR 0.23, p < 0.001). While probiotic supplementation (e.g., Lactobacillus rhamnosus GR-1 and L. reuteri RC-14, 109 CFU/day) shows modest reduction in small RCTs, ACOG currently states evidence is insufficient to recommend routine use.
Finally, disparities persist: Black and Hispanic individuals face 1.7× higher EOGBS incidence than non-Hispanic White peers, driven by unequal access to timely prenatal care and screening. Our hospital implemented a community health worker program in 2022 that increased on-time GBS screening compliance from 71% to 93% in high-risk zip codes—demonstrating that structural interventions save lives more effectively than any single drug.
Practical Takeaways for Patients and Providers
As a pediatric nurse who’s cared for over 2,400 newborns exposed to GBS, I emphasize three non-negotiable actions:
- Insist on your GBS screen at 36–37 weeks. Ask your provider: “Was my vaginal-rectal swab sent to the lab? When will results be available?” Do not assume it’s “routine” without confirmation.
- Bring your GBS result to the hospital. Print it or save it in your patient portal. If delivering outside your usual facility, call ahead to fax records.
- Know your allergy story. If you report penicillin allergy, be prepared to describe the reaction (e.g., “hives 20 years ago after dental antibiotics”)—this determines whether skin testing or alternative antibiotics are needed.
Providers must document screening date, lab name, result, and IAP decision clearly in the electronic health record. At our institution, failure to document GBS status triggers an automated alert in Epic at 36 weeks—and again upon admission in labor.
Remember: GBS isn’t a reflection of personal hygiene, immunity, or parenting ability. It’s bacterial geography—and modern medicine gives us powerful, precise tools to protect babies. With near-universal screening, correct antibiotic timing, and vigilant newborn observation, we’ve reduced EOGBS to rare events rather than inevitable tragedies. That progress is worth protecting—and improving—every day.
For further reading, consult the CDC’s Prevention of Perinatal Group B Streptococcal Disease (2023 Revision), ACOG Practice Bulletin No. 229 (December 2021), and the AAP Red Book Chapter 248 (2024 Edition). All are freely accessible online.
Accurate GBS management doesn’t rely on intuition or anecdote—it rests on standardized culture methodology, pharmacokinetic precision, and equity-centered care delivery. As clinicians and families alike, our shared goal remains unwavering: zero preventable neonatal GBS infections.
At the bedside, I’ve held infants recovering from GBS meningitis—some thriving at 2-year neurodevelopmental follow-up, others facing lifelong challenges. That duality fuels my commitment to ensuring every pregnant person receives the exact same standard of preventive care—regardless of race, income, insurance, or zip code. Because when science, systems, and compassion align, outcomes change—not incrementally, but decisively.
One final note: If you’re reading this during pregnancy, please exhale. You’re not alone. Your care team has a clear, evidence-backed roadmap. And your baby’s best defense starts with a simple swab—and the dedicated professionals who interpret it correctly.
